Adjuvant high-dose interferon-alpha therapy for high-rish melanoma

FORUM - Trends in Experimental and Clinical Medicine

Volumn 13, Issue 2, 2003, Pages 127-143

  Kirkwood, John M ^a   Tarhini, Ahmad A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Interferon; Melanoma; Therapy

Indexed keywords

2,4 DINITROPHENOL; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHA2C INTERFERON; ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CORYNEBACTERIUM PARVUM EXTRACT; DACARBAZINE; GANGLIOSIDE GM2; GANGLIOSIDE VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LEVAMISOLE; MEGESTROL ACETATE; MELACINE; MELAN A; MELANOMA VACCINE; MONOPHENOL MONOOXYGENASE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; PEPTIDE DERIVATIVE; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; FATALITY; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INFECTION; ISCHEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PROGNOSIS; REPRODUCIBILITY; REVIEW; ULCER; VOMITING; ADJUVANT CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; SKIN NEOPLASMS;

EID: 33749001751     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Rigel DS. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA-A Cancer J. Clin. 2000; 50: 215-236.
2. Jemal A et al. Cancer Statistics, 2002. JA Cancer J. Clin. 2002; 52: 23-47.
3. Balch CM et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 2001; 19: 3635-3648.
4. Kirkwood JM. Melanoma of the skin. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG et al. (American Joint Committee on Cancer) Cancer Staging Manual, Sixth ed. New York: Springer, 2002; 209-220.
5. Manola et al. Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials. Proc. Am. Soc. Clin. Oncol. 2000: 19, 551a.
6. Kirkwood JM, Agarwala S. Systemic cytotoxic and biologic therapy melanoma. Cancer Principles and Practice of Oncology 1993; 7: 1-16.
7. Balch CM et al. Prognostic factors analysis of 17,600 melanoma patients. Validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 2001; 19: 3622-3634.
8. Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. Ann. Intern. Med. 1996; 125: 369.
9. Balch CM et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484-1491.
10. Veronesi U et al. A randomised trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N. Engl. J. Med. 1982; 307: 913-916.
11. Banzet P et al. Adjuvant chemotherapy in the management of primary malignant melanoma. Cancer 1978; 41: 1240-1248.
12. Morton DL et al. BCG immunotherapy of malignant melanoma: Summary of a seven-year experience. Ann. Surgery 1974; 180: 635-643.
13. Lipton A et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer 1983; 51: 57-60.
14. Balch CM et al. A randomised prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (stage I): Prognostic factors analysis and preliminary results of immunotherapy. Cancer 1982; 49: 1079-1084.
15. Lipton A et al. Corynebacterium parvum versus Bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J. Clin. Oncol. 1991; 9:1151-1156.
16. Loutfi A et al. Double blind randomised prospective trial of levamisole/ placebo in stage I cutaneous melanoma. Clin. Invest. Med. 1987; 10: 325-328.
17. Spitler LE. A randomised trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. J. Clin. Oncol. 1991; 9: 736-740.
18. Parkinson DR. Levamisole as adjuvant therapy for melanoma: Quo vidis? J. Clin. Oncol. 1991; 9: 716-717.
19. Morton DL et al. Polyvalent melanoma vaccine improves survival of patients with metatatic melanoma. Ann NY Acad Sci 1993; 690: 120-134.
20. DiFronzo L et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J. Clin. Oncol. 2002; 20: 3242-3248.
21. Lotem M et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). Br. J. Cancer 2002; 86: 1534-1539.
22. Berd D et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastasis. J. Clin. Oncol. 1997; 15: 2359-23570.
23. Sondak VK et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: overall results of a randomised trial of the Southwest Oncology Group. J. Clin. Oncol. 2002; 20: 2058-2066.
24. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 1998; 25: 623-635.
25. Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res. 1995; 139: 337-348.
26. Livingston PO et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomised trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994; 12: 1036-1044.
27. Kirkwood JM et al. High-dose interferon alfa-2b significantly prolongs relapse-free and over-all survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001; 19: 2370-2380.
28. Agarwala S and Kirkwood J. Update on adjuvant interferon therapy for high-risk melanoma. Oncology 2002; 16: 1177-1191.
29. Kirkwood JM. Biological Therapy of Cancer. Cancer 2000.
30. Hakansson A et al. Tumor-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br. J. Cancer 1996; 74: 670-676.
31. + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J. Immunol. 1998; 161: 2804-2809.
32. Mailliard. R et al. Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper tote of CD8+ T cells in the development of T helper type 1 responses. J. Exp. Med. 2002; 195: 473-483.
33. Chakrabarti D et al. IFN-alpha induces autoimmune T cells through the induction of aintracellular adhesion molecule-1 and B7.2. J. Immunol. 1996; 157:522-528.
34. Ernstoff MS et al. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Cancer Res. 1992; 52: 851-856.
35. Kirkwood JM et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002; 95: 1101-1112.
36. Kleeberg UR et al. Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to Iscador to a control group after curative resection of high risk primary (≥3 mm) or regional lymph node metastasis (EORTC 18871). (Abstract) Eur. J. Cancer 35 (suppl 4): A-264, s82, 1999.
37. Kirkwood JM et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 1996; 14: 7-17.
38. Kirkwood JM et al. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. J. Clin. Oncol. 2000; 18: 2444-2458.
39. M2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995; 55: 2783-2788.
40. Livingston PO et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioslide-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12: 1275-1280.
41. Kirkwood JM et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696. J. Clin. Oncol. 2001; 19: 1430-1436.
42. Creagan ET et al. Randomised, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J. Clin. Oncol. 1995; 13: 2776-2783.
43. Cascinelli N et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358: 866-869.
44. Hancock BW et al. Aim high-adjuvant interferon in melanoma (high risk), a United Kingdon Co-Ordinating Committee on Cancer Research (UKCCR) randomised study of observation versus adjuvant low dose extended duration interferon alpha-2a in high risk resected malignant melanoma. Proc. Ass. Soc. Clin. Oncol. 2002; 20: 349a.
45. Kikey KE, Gale DM. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b. Clin J Oncol Nurs. 1998; 2: 11-16.
46. Caraceni A et al. Neurotoxicity of interferon-α in melanoma therapy: Results from a randomised controlled trial. Cancer 1998; 83: 482-489.
47. Greenberg DB et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89: 356-362.
48. Quesada JR et al. Clinical toxicity of interferons in cancer patients: a review. J. Clin. Oncol. 1986; 4: 234-243.
49. Kirkwood JM et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 2002; 20: 3703-3718.
50. Kirkwood JM. Adjuvant IFNα2 therapy of melanoma. Lancet 1998; 351: 1901-1903.
51. Cascinelli, N. Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases. Proc. Ass. Soc. Clin. Oncol. 1995; 14, A1296.
52. Grob JJ et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-1910.
53. Pehamberger H et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J. Clin. Oncol. 1998; 16: 1425-1429.
54. Cole BF et al. A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group Study (E1684). J. Clin. Oncol. 1996; 14: 2666-2673.
55. Hillner BE et al. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from ECOG 1684. J. Clin. Oncol. 1997; 15: 2351-2358.
56. Messori A et al. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur. J. Cancer 1997; 33: 1373-1379.
57. Kilbridge KL et al. Quality-of-life adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data. J. Clin. Oncol. 2002; 20: 1311-1318.
58. Kilbridge et al. Quality-of-life (QOL) adjusted analysis of high-dose adjuvant interferon alfa-2B (HDI) for melanoma based on E1694/S9512/ C509801, E1690/S9111/C9190 and E1684. Am. Soc. Clin. Oncol. 2002; abs. 1398.
59. Szabolcs P et al. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocytemacrophage colony-stimulating factor, and TNF-alpha. J. Immunol. 1995; 154:5851-5861.
60. Grabstein KH et al. Induction of macrophage tumoricidal activity by granulocytemacrophage colony-stimulating factor. Science 1986; 232: 506-508.
61. Spitler LE et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor (GM-CSF). J. Clin. Oncol. 2000; 18: 1614-1621.
62. Soiffer R et al. Induction of anti-tumour immunity by autologous melanoma vaccines genetically engineered to secrete granulocytemacrophage colony-stimulating factor (G-CSF). Proc. Am. Soc. Clin. Oncol. 1997; 16: 489a.
63. Soiffer R, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 1998; 95: 13141-13146.
64. Rankin EM et al. Immunomodulation following vaccination with autologous, GM-CSF transduced and irradiated tumour cells in patients with advanced melanoma. Proc. An. Soc. Clin. Oncol. 1997; 16: 489a.
65. Riccardi A et al. Oxaliplatin activity in neuroblastoma (NB) cell lines. Proc. Am. Ass. Cancer Res. 1998; 39: 159.
66. Jaeger E et al. GM-CSF enhances immune responses in melanoma-associated peptides in vivo. Int. J. Cancer 1996; 67: 54-62.
67. Van den Eynde B et al. Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int. J. Cancer 1989, 44: 634-640.
68. Anichini A et al. Cytotoxic T lymphocyte clones from peripheral blood and from tumour site detect intratumor heterogeneity of melanoma cells: Analysis of specificity and mechanisms of interaction. J. Immunol. 1989; 142: 3692-36701.
69. Wolfel T et al. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J. Exp. Med. 1989; 170: 797-810.
70. Hom SS et al. Common expression of melanoma associated-associated antigens recognized by human tumour infiltrating lymphocytes: Analysis by human lymphocyte antigen restriction. J. Immunother. 1991; 10: 153-164.
71. Gaugler B et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytotoxic T lymphocytes. J. Exp. Med. 1994; 179: 921-930.
72. Wolfel T et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolyticT lymphocytes. Eur. J. Immunol. 1994; 24: 759-764.
73. Cox AL et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-719.
74. Crowley NJ et al. MHC-restricted recognition of autologous melanoma by specific-specific cytotoxic T cells: Evidence for restriction by a dominant HLA-A allele. J. Immunol. 1991; 146: 1692-1699.
75. Storkus WJ et al. Identification of human melanoma peptides recognized by class restricted tumour infiltrating T lymphocytes. J. Immunother. 1993;151:3719-3727.
76. Slingluff CL et al. Recognition of human melanoma cells by HLA-A2. 1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 1993; 150: 2955-2963.
77. Kawakami Y et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc. Natl. Acad. Sci. USA 1994; 91: 3515-3519.
78. Coulie PG et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994; 180: 35-42.
79. Anichini A et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 1993; 177: 989-998.
80. Kawakami Y et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumour infiltrating lymphocytes. J. Exp. Med. 1994; 180: 347-352.
81. Traversari C et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J. Exp. Med. 1992; 176: 1453-1457.
82. Mandelboim O et al. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 67-71.
83. Castelli C et al. Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J. Exp. Med. 1995; 181: 363-368.
84. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998; 4: 321-327.